← Dashboard
Stock
BSX
BOSTON SCIENTIFIC CORPHealth CareHealth Care EquipmentLatest close $5610 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
10
27 funds tracked
Ever held
18
Current + past
New this quarter
0
Exited this quarter
1
Marquee-fund ownership over time
Aug 14, 2013Nov 14, 2018Feb 14, 2023May 15, 2026
Now
10
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q1 2014 | 50Q | $13 | $56 | +331% |
| Maverick Capital re-entered | Q2 2018 | 33Q | $30 | $56 | +89% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $76 | $56 | -27% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $76 | $56 | -27% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $76 | $56 | -27% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $76 | $56 | -27% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $76 | $56 | -27% |
| Point72 Asset Management | Q3 2024(8Q snapshot) | 7Q | $76 | $56 | -27% |
| Renaissance Technologies re-entered | Q4 2024(8Q snapshot) | 6Q | $89 | $56 | -37% |
| Lone Pine Capital | Q1 2026 | 1Q | $76 | $56 | -27% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Viking Global Investors 4× in & out | Q4 2024 | Q2 2026 | → $53 | -40% |
| Soros Fund Management | Q3 2024 | Q3 2025 | → $104 | +36% |
| D1 Capital Partners | Q4 2022 | Q1 2023 | → $47 | +12% |
| Glenview Capital | Q2 2020 | Q1 2023 | → $47 | +36% |
| Appaloosa 2× in & out | Q2 2020 | Q1 2021 | → $38 | +9% |
| Third Point | Q2 2019 | Q2 2020 | → $35 | -6% |
| JANA Partners | Q2 2018 | Q2 2019 | → $37 | +25% |
| Duquesne Family Office | Q3 2013 | Q4 2013 | → $12 | +6% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at BOSTON SCIENTIFIC CORP. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
15
Filings · last 90d
20
Total on file
674
Recent SEC buffer
Most recent
Jun 1, 2026
30d / 90d windows measured from Jun 1, 2026 — the most recent Form 4 on file — not from today.
- Form 40001225208-26-005670Jun 1, 2026
- Form 40001225208-26-005548May 21, 2026
- Form 40001225208-26-005547May 21, 2026
- Form 40001225208-26-005546May 21, 2026
- Form 40001225208-26-005115May 11, 2026
- Form 40001225208-26-005114May 11, 2026
- Form 40001225208-26-005113May 11, 2026
- Form 40001225208-26-005112May 11, 2026
- Form 40001225208-26-005111May 11, 2026
- Form 40001225208-26-005110May 11, 2026
- Form 40001225208-26-005109May 11, 2026
- Form 40001225208-26-005108May 11, 2026
- Form 40001225208-26-005107May 11, 2026
- Form 40001225208-26-004897May 4, 2026
- Form 40001225208-26-004896May 4, 2026
Showing 15 of 674 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · BOSTON SCIENTIFIC CORPAnnual figures sourced directly from BOSTON SCIENTIFIC CORP's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$20.07B
FY2025+20% YoY
EPS (diluted)
$1.94
FY2025+55% YoY
Free cash flow(?)
$3.66B
FY2025+38% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for BOSTON SCIENTIFIC CORP — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 18, 2026
- 8-KMaterial eventMay 18, 2026
- 8-KMaterial eventMay 5, 2026
- 10-QQuarterly reportMay 1, 2026
- 8-KMaterial eventApr 22, 2026
- S-4/ARegistration (M&A, amended)Mar 30, 2026
- 8-KMaterial eventMar 30, 2026
- DEF 14AProxy statementMar 18, 2026
- S-4Registration (M&A)Feb 27, 2026
- 8-KMaterial eventFeb 26, 2026
- 8-KMaterial eventFeb 23, 2026
- 10-KAnnual reportFeb 17, 2026
- 8-KMaterial eventFeb 5, 2026
- 8-KMaterial eventFeb 4, 2026
- 8-KCURRENT REPORTJan 15, 2026
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Lone Pine Capital | Q1 2026 | open | $76 | $48 | -37% |
| Maverick Capital | Q1 2026 | open | $75 | $48 | -35% |
| Renaissance Technologies | Q2 2025 | open | $103 | $56 | -46% |
| Viking Global Investors | Q4 2024 | Q2 2026 | $88 | $53 | -40% |
| Renaissance Technologies | Q4 2024 | Q1 2025 | $89 | $106 | +20% |
| Citadel Advisors | Q3 2024 | open | $76 | $56 | -27% |
| Soros Fund Management | Q3 2024 | Q3 2025 | $76 | $104 | +36% |
| Two Sigma Investments | Q3 2024 | open | $76 | $56 | -27% |
| D.E. Shaw | Q3 2024 | open | $76 | $56 | -27% |
| AQR Capital Management | Q3 2024 | open | $76 | $56 | -27% |
| Millennium Management | Q3 2024 | open | $76 | $56 | -27% |
| Point72 Asset Management | Q3 2024 | open | $76 | $56 | -27% |
| Maverick Capital | Q1 2024 | Q3 2024 | $66 | $76 | +16% |
| Viking Global Investors | Q4 2023 | Q3 2024 | $54 | $76 | +41% |
| D1 Capital Partners | Q4 2022 | Q1 2023 | $42 | $47 | +12% |
| Maverick Capital | Q4 2020 | Q1 2022 | $38 | $43 | +12% |
| Bridgewater Associates | Q4 2020 | open | $38 | $48 | +27% |
| Appaloosa | Q2 2020 | Q1 2021 | $35 | $38 | +9% |
| Glenview Capital | Q2 2020 | Q1 2023 | $35 | $47 | +36% |
| Bridgewater Associates | Q2 2020 | Q3 2020 | $36 | $40 | +13% |
| Third Point | Q2 2019 | Q2 2020 | $37 | $35 | -6% |
| Bridgewater Associates | Q2 2019 | Q1 2020 | $37 | $42 | +15% |
| Maverick Capital | Q1 2019 | Q2 2019 | $40 | $37 | -7% |
| Viking Global Investors | Q4 2018 | Q3 2023 | $36 | $51 | +42% |
| Maverick Capital | Q2 2018 | Q3 2018 | $30 | $34 | +14% |
| JANA Partners | Q2 2018 | Q2 2019 | $30 | $37 | +25% |
| Bridgewater Associates | Q1 2018 | Q3 2018 | $26 | $33 | +28% |
| Appaloosa | Q1 2017 | Q1 2019 | $25 | $40 | +59% |
| Viking Global Investors | Q4 2015 | Q1 2016 | $18 | $17 | -3% |
| Bridgewater Associates | Q4 2014 | Q2 2017 | $13 | $26 | +97% |
| Bridgewater Associates | Q1 2014 | Q3 2014 | $13 | $12 | -5% |
| Duquesne Family Office | Q3 2013 | Q4 2013 | $11 | $12 | +6% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.